Key Highlights

  • Imagion executed a clinical trial agreement with Regis Clinical Research, the first site formally engaged for the Phase 1b/2 trial.
  • The trial is now registered on ClinicalTrials.gov, and site initiation is underway at seven sites in total.
  • The trial is designed in three parts, with an expected duration of 18 to 24 months and interim analyses after Parts A and B.
  • The principal investigator is Dr Eghtedari of City of Hope in Los Angeles.

Imagion Biosystems Limited (ASX:IBX) announced on 17 November 2026 that it had executed a clinical trial agreement with Regis Clinical Research, making it the first US site formally engaged for the Phase 1b/2 trial of its MagSense HER2 imaging agent in HER2-positive breast cancer. The clinical-stage medical imaging company said the agreement allows site activation and patient recruitment to move forward, and the trial has been formally registered on ClinicalTrials.gov.

Trial Design and Timeline

The trial is designed in three parts. Part A is a pharmacokinetic cohort of up to 10 subjects intended to collect further safety data, as agreed with the US Food and Drug Administration. Part B, with about 20 subjects, will test the reduced dosing regimen and optimised imaging protocol to establish the lowest effective dose and imaging schedule. Part C, with about 40 subjects, will compare diagnostic performance against standard care.

The trial is expected to be completed in 18 to 24 months, with interim analyses after Parts A and B. Dr Eghtedari, Section Chief of Women's Imaging at City of Hope, will act as principal investigator. The company said Dr Eghtedari also served as an independent reviewer of the earlier Phase 1 trial.

Clinical Context

The company cites an estimated 450,000 women diagnosed with HER2-positive breast cancer each year worldwide. Imagion says precise nodal staging is needed to guide treatment, and that ultrasound, the most common method, shows wide variability in sensitivity and specificity.

Imagion reports that independent radiologists in the completed Phase 1 trial found the agent produced a readily identifiable change in MRI images separating tumour-involved from non-involved nodes. The Phase 1b/2 trial is intended to set the optimised dose and imaging timing and to assess diagnostic performance.

Site Activation and Next Steps

Patient recruitment is expected to begin shortly after site initiation activities. Beyond Regis, seven sites have been selected to take part to date, and the company is working to finalise contracts and activate them. Site-specific startup work includes investigator Training and site activation.

Sector Context and Risks to Watch

Clinical programmes of this kind depend on site contracting, patient enrolment and regulatory alignment, and each stage can take longer than planned. The company's own timeline spans 18 to 24 months, and the number of sites that move to activation will affect recruitment speed.

The main risks identified in the announcement are the time to activate the remaining sites, the pace of patient recruitment and the results of the interim analyses. Future updates are expected to report site activations and the start of enrolment.

Final Word

Imagion has secured its first US trial site and registered the Phase 1b/2 study, with seven sites in initiation. The next updates are expected to report activation of further sites, the start of patient recruitment and the outcome of the interim analyses after Parts A and B.